NCT01014351已完成2 期
A Phase II Study of Everolimus in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 70
- 试验地点
- 12
- 主要终点
- Progression-free Survival (PFS)
研究概览
简要总结
Based on data demonstrating synergy between paclitaxel and mammalian target of rapamycin (mTOR) inhibition, the investigators propose that the addition of everolimus to paclitaxel with carboplatin should lead to improvements in efficacy as measured by progression-free survival and response rate.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed metastatic melanoma.
- •Stage III or IV disease that is not amenable to resection.
- •Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.
- •If the patient has had previous radiation to the target lesion(s), there must be evidence of progression since the radiation.
- •ECOG Performance Status of 0 or
- •Life expectancy ≥12 weeks.
- •No prior cytotoxic chemotherapy or targeted therapy. Immunotherapy is allowed (i.e., interleukin-2 or interferon).
- •Adequate hematological function:
- •absolute neutrophil count (ANC) ≥1500/µL and
- •platelets ≥100,000/µL and
- •hemoglobin >9 g/dL
- •Adequate renal function: serum creatinine ≤2.0 mg/dL or calculated (measured) GFR ≥50 mL/min.
- •Adequate hepatic function:
- •serum bilirubin ≤1.5 x institutional upper limit of normal (ULN);
- •aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN, or ≤5 × ULN in patients with documented liver metastases.
- •Normal PT, INR. Patients on coumadin anticoagulation are eligible if they are on a stable dose, with an INR in the therapeutic range.
- •Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fasting triglycerides ≤ 2.5 x ULN. NOTE: In case one or both of these thresholds are exceeded, the patient can be included after initiation of appropriate lipid lowering medication.
- •Age ≥18 years.
- •Ability to swallow whole pills.
- •Patient must be accessible for treatment and follow-up.
- •Patients must be able to understand the investigational nature of this study and give written informed consent prior to study entry.
排除标准
- •Previous treatment with an mTOR inhibitor (sirolimus, temsirolimus, everolimus), paclitaxel, or carboplatin.
- •Treatment with any investigational agent ≤4 weeks of protocol treatment.
- •Patients currently receiving anticancer therapies or who have received anticancer therapies ≤3 weeks of the start of the study drug (including radiation therapy, immunotherapy).
- •Patients, who have had a major surgery or significant traumatic injury ≤4 weeks of start of study drug or patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia).
- •Patients receiving chronic, systemic treatment with corticosteroids (dose >10 mg daily of methylprednisolone or equivalent) or other immunosuppressive agents. Topical or inhaled steroids are allowed.
- •Immunization with attenuated live vaccine ≤1 week of study or anytime during study treatment period.
- •Patients with active brain metastases are ineligible. Patients with treated brain metastases are eligible if (1) radiation therapy was completed ≥4 weeks prior to study entry; (2) surgery was completed ≥4 weeks prior to study entry; (3) follow-up scan shows no disease progression; and (4) patient does not require steroids.
- •Any severe and/or uncontrolled medical conditions or other conditions that could affect participation in the study such as:
- •severely impaired lung function defined as a DLCO ≤50% of the normal predicted value and/or O2 saturation ≤88% at rest on room air.
- •symptomatic congestive heart failure of New York Heart Association Class III or IV.
- •unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤6 months of start of study drug, serious uncontrolled cardiac arrhythmia or any other clinically significant disease.
- •uncontrolled diabetes as defined by fasting serum glucose >1.5 x ULN.
- •active (acute or chronic) uncontrolled severe infections.
- •liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis.
- •Active, bleeding diathesis.
- •Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
- •A known history of human immunodeficiency virus (HIV) seropositivity.
- •Known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients.
- •Use of St. John's Wort is prohibited. Drugs or substances (e.g., grapefruits, star fruits, seville oranges, and their juices and products), known to be inhibitors or inducers of the isoenzyme CYP3A4 should be avoided. Co-administration with substrates, inducers, or inhibitors of P glycoprotein should also be avoided.
- •Female patients who are pregnant or breastfeeding or adults of reproductive potential who are not using effective birth control methods. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes. Hormonal contraceptives are not acceptable as a sole method of contraception. (Women of childbearing potential [WOCBP] must have a negative urine or serum pregnancy test within 7 days prior to administration of everolimus.) WOCBP should continue to use effective contraception for 8 weeks after ending everolimus treatment.
- •Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin.
- •History of noncompliance to medical regimens. Patients unwilling to, or unable to, comply with the protocol.
- •History of any other disease, physical examination finding, or clinical laboratory finding that gives reasonable suspicion of a disease or a condition that may render the patient at high risk for treatment complications using these agents.
研究组 & 干预措施
Paclitaxel/Carboplatin/Everolimus
Experimental
Systemic Therapy using everolimus, paclitaxel and carboplatin given during a 21-day treatment cycle
干预措施: Paclitaxel (Drug)
Paclitaxel/Carboplatin/Everolimus
Experimental
Systemic Therapy using everolimus, paclitaxel and carboplatin given during a 21-day treatment cycle
干预措施: Carboplatin (Drug)
Paclitaxel/Carboplatin/Everolimus
Experimental
Systemic Therapy using everolimus, paclitaxel and carboplatin given during a 21-day treatment cycle
干预措施: Everolimus (Drug)
结局指标
主要结局
Progression-free Survival (PFS)
时间窗: 18 months
Progression-free survival (PFS) is defined as the time from randomization until objective tumor progression (PD) or death. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
次要结局
- Overall Survival (OS)(18 months)
- Objective Response Rate (ORR)(18 months)
研究者
研究点 (12)
Loading locations...
相似试验
终止
2 期
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial CarcinomaTransitional Cell CarcinomaUrothelial CarcinomaBladder CarcinomaNCT01215136Matthew Galsky36
已完成
2 期
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath TumorsMalignant Peripheral Nerve Sheath TumorsSarcomaMPNSTNCT01661283Sarcoma Alliance for Research through Collaboration25
终止
2 期
Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell CarcinomaSquamous Cell CarcinomaNCT01009203New Mexico Cancer Care Alliance13
已完成
2 期
Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NETGastrointestinal NeoplasmsNCT01567488Grupo Espanol de Tumores Neuroendocrinos43
已完成
1 期
Study of Everolimus (RAD001) in Combination With LenalidomideSolid Organ MalignanciesAdenoidcystic CarcinomaNeuroendocrine TumorsNCT01218555Emory University44